1. Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride
- Author
-
Keita Matsumoto, Satohiro Matsumoto, Takeshi Uehara, Takaya Miura, Yudai Koito, Kazuhito Yuhashi, Takehiro Ishii, Junichi Fujiwara, Masanari Sekine, Mina Morino, Takeharu Asano, Shinichi Asabe, Hirosato Mashima, Haruka Otake, Hitomi Kashima, Yuko Takahashi, Shuhei Yoshikawa, Rumiko Tsuboi, and Hiroyuki Miyatani
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual analog scale score ,Adolescent ,Science ,Chronic liver disease ,Gastroenterology ,Article ,End Stage Liver Disease ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Refractory ,Internal medicine ,medicine ,Humans ,In patient ,Spiro Compounds ,skin and connective tissue diseases ,Aged ,Hepatitis ,Aged, 80 and over ,Multidisciplinary ,Hepatology ,integumentary system ,business.industry ,Nalfurafine Hydrochloride ,Pruritus ,Middle Aged ,medicine.disease ,body regions ,Treatment Outcome ,Morphinans ,030220 oncology & carcinogenesis ,Medicine ,030211 gastroenterology & hepatology ,Female ,business ,Complication ,Nalfurafine ,medicine.drug - Abstract
Pruritus is known to be a common complication in hepatitis patients, but the exact frequency and degree are not fully elucidated. Thus, we evaluated pruritus of 450 patients with chronic liver disease at our hospital. Pruritus was observed in 240 (53%) of the patients. Pruritus was significantly associated with males (OR = 1.51, P = 0.038) and patients with alkaline phosphatase (ALP) ≥ 200 U/L (OR = 1.56, P = 0.0495) and was significantly less in HBsAg-positive patients (OR = 0.449, P = 0.004). Seasonally, there was no difference in the frequency of pruritus between summer and winter. Of the 24 refractory pruritus patients treated with nalfurafine, 17 (71%) indicated improvement of itch, which is defined as a decrease in the visual analog scale score ≥ 30 mm. Pruritus was improved by nalfurafine both during daytime and nighttime in the Kawashima’s scores evaluation. All patients who received nalfurafine exhibited improved Kawashima’s scores ≥ 1 point during the daytime or nighttime. In conclusion, pruritus occurred in > 50% of patients with chronic liver disease, and predictors of pruritus were males and ALP ≥ 200 U/L. Nalfurafine may be useful for pruritus, regardless of whether daytime or nighttime.
- Published
- 2021